...
首页> 外文期刊>Journal of cell biology >Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.
【24h】

Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.

机译:趋化因子在淋巴细胞与内皮和细胞外基质相互作用期间调节细胞极化和粘附受体的重新分布。 cAMP信号通路的参与。

获取原文

摘要

Leukocyte recruitment is a key step in the inflammatory reaction. Several changes in the cell morphology take place during lymphocyte activation and migration: spheric-shaped resting T cells become polarized during activation, developing a well defined cytoplasmic projection designated as cellular uropod. We found that the chemotactic and proinflammatory chemokines RANTES, MCP-1, and, to a lower extent, MIP-1 alpha, MIP-1 beta, and IL-8, were able to induce uropod formation and ICAM-3 redistribution in T lymphoblasts adhered to ICAM-1 or VCAM-1. A similar chemokine-mediated effect was observed during T cells binding to the fibronectin fragments of 38- and 80-kD, that contain the binding sites for the integrins VLA-4 and VLA-5, respectively. The uropod structure concentrated the ICAM-3 adhesion molecule (a ligand for LFA-1), and emerged to the outer milieu from the area of contact between lymphocyte and protein ligands. In addition, we found that other adhesion molecules such as ICAM-1, CD43, and CD44, also redistributed to the lymphocyte uropod upon RANTES stimulation, whereas a wide number of other cell surface receptors did not redistribute. Chemokines displayed a selective effect among different T cell subsets; MIP-1 beta had more potent action on CD8+ T cells and tumor infiltrating lymphocytes (TIL), whereas RANTES and MIP-1 alpha targeted selectively CD4+ T cells. We have also examined the involvement of cAMP signaling pathway in uropod formation. Interestingly, several cAMP agonists were able to induce uropod formation and ICAM-3 redistribution, whereas H-89, a specific inhibitor of the cAMP-dependent protein kinase, abrogated the chemokine-mediated uropod formation, thus pointing out a role for cAMP-dependent signaling in the development of this cytoplasmic projection. Since the lymphocyte uropod induced by chemokines was completely abrogated by Bordetella pertussis toxin, the formation of this membrane projection appears to be dependent on G proteins signaling pathways. In addition, the involvement of myosin-based cytoskeleton in uropod formation and ICAM-3 redistribution in response to chemokines was suggested by the prevention of this phenomenon with the myosin-disrupting agent butanedione monoxime. Interestingly, this agent also inhibited the ICAM-3-mediated cell aggregation, but not the cell adhesion to substrata. Altogether, these results demonstrate that uropod formation and adhesion receptor redistribution is a novel function mediated by chemokines; this phenomenon may represent a mechanism that significantly contributes to the recruitment of circulating leukocytes to inflammatory foci.
机译:白细胞募集是炎症反应中的关键步骤。在淋巴细胞激活和迁移过程中,细胞形态发生了一些变化:球形的静止T细胞在激活过程中被极化,形成定义明确的胞质投射,称为细胞尾足。我们发现趋化性和促炎性趋化因子RANTES,MCP-1,以及较低程度的MIP-1 alpha,MIP-1 beta和IL-8能够诱导T淋巴母细胞形成uropod和ICAM-3重新分布。遵守ICAM-1或VCAM-1。在T细胞与38kD和80kD的纤连蛋白片段结合的过程中,观察到了类似的趋化因子介导的作用,这些片段分别包含整联蛋白VLA-4和VLA-5的结合位点。 uropod结构浓缩了ICAM-3粘附分子(LFA-1的配体),并从淋巴细胞和蛋白质配体之间的接触区域露出到外部环境。此外,我们发现其他粘附分子,例如ICAM-1,CD43和CD44,在RANTES刺激下也重新分布到淋巴细胞uropod,而许多其他细胞表面受体却没有重新分布。趋化因子在不同的T细胞亚群中表现出选择性作用。 MIP-1 beta对CD8 + T细胞和肿瘤浸润淋巴细胞(TIL)具有更强的作用,而RANTES和MIP-1 alpha选择性靶向CD4 + T细胞。我们还检查了cAMP信号通路在尾足形成中的参与。有趣的是,几种cAMP激动剂能够诱导尿嘧啶形成和ICAM-3重新分布,而H-89,一种cAMP依赖性蛋白激酶的特异性抑制剂,废除了趋化因子介导的uropod形成,从而指出了cAMP依赖性的作用信号在这种细胞质投射的发展。由于趋化因子诱导的淋巴细胞uropod被百日咳博德特氏菌毒素完全消除,因此这种膜突起的形成似乎取决于G蛋白信号通路。另外,通过用肌球蛋白破坏剂丁烷二酮单肟预防这种现象,表明基于肌球蛋白的细胞骨架参与了uropod的形成和ICAM-3对趋化因子的响应的重新分布。有趣的是,该试剂还抑制了ICAM-3介导的细胞聚集,但不抑制细胞与基质的粘附。总之,这些结果表明,uropod的形成和粘附受体的重新分布是趋化因子介导的一种新功能。这种现象可能代表了一种机制,可极大地促进循环白细胞募集至炎症灶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号